What VaRi bioscience does

VaRi Bioscience GmbH is a development-stage women's health biotechnology company founded in 2020 and headquartered in Wildau, Germany, near Berlin. The company is developing a portfolio of vaginal ring drug delivery products targeting three indications: contraception (VR101, a non-invasive long-acting progestin-only ring for women with estrogen contraindications), vulvovaginal atrophy (VR102, a first-in-class long-acting local estrogen therapy ring), and endometriosis (VR103, a long-acting progestin therapy). The core technology is a proprietary polymer-based vaginal ring platform using EVA copolymer that releases active ingredients at predetermined rates over periods ranging from one month to five years via extrusion and ring-closure molding manufacturing processes.

The business model centers on pharmaceutical product sales upon regulatory approval across three addressable patient populations: approximately 40% of fertile women in the US with estrogen contraindications for contraception, approximately 36 million prevalent VVA cases across seven major markets, and roughly 10% of women of reproductive age affected by endometriosis. Pricing is not publicly disclosed as products remain in Phase I/II clinical trials. Manufacturing is outsourced to specialized Contract Manufacturing Organizations (CMOs) for clinical and commercial supply, allowing VaRi to focus internal resources on product development and regulatory activities. The company operates across Europe and North America and is currently privately held with one disclosed equity financing event from Aristo Pharma GmbH in December 2023.

VaRi Bioscience's competitive position rests on a senior management team drawn from Schering AG, Bayer, Organon, and Evestra, including multiple executives with 15-28 years of pharmaceutical R&D experience. The company publicly seeks additional financial and strategic investors to support growth, and is building its intellectual property portfolio around the vaginal ring platform technology. Distribution channels, pricing models, and commercial infrastructure are not yet established given the development-stage status, with commercialization likely dependent on out-licensing, partnership with larger pharmaceutical companies, or future direct launch once products receive regulatory approval.

Name

VaRi bioscience

Legal name

VaRi Bioscience GmbH

Website

https://vari-bioscience.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

VaRi Bioscience GmbH is a development-stage German women's health biotechnology company founded in 2020, developing a pipeline of three vaginal ring products for contraception (VR101), vulvovaginal atrophy (VR102), and endometriosis (VR103) using proprietary polymer drug delivery technology.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Vaginal drug delivery
• Women's health therapeutics
• Long-acting contraceptives
• Polymer pharmaceutical formulations
• Hormone replacement therapy

Headquarters

HQ city

Wildau

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: The company is developing vaginal ring products for women's health indications including contraception, vulvovaginal atrophy, and endometriosis. Revenue will be generated through product sales upon regulatory approval.

Distribution channels1 record

Marketing channels4 records

Core offering

VaRi Bioscience develops a portfolio of vaginal ring pharmaceutical products for women's health indications, leveraging a proprietary polymer-based drug delivery platform. The technology releases active ingredients at predetermined rates over one month to five years and is being applied to three pipeline candidates: VR101 (long-acting progestin-only contraception), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). Products are designed to provide non-invasive, long-term treatment with minimal systemic exposure, and are manufactured in partnership with specialized contract manufacturing organizations.

Product overview

VaRi Bioscience is a biotech company developing a portfolio of vaginal ring products for women's health indications. The core platform is the women's-specific vaginal ring drug delivery technology that enables long-term treatment with minimal systemic exposure. Current pipeline includes three products: VR101 (progestin-only contraceptive), VR102 (local estrogen therapy for vulvovaginal atrophy), and VR103 (endometriosis therapy). The technology bypasses first-pass metabolism in the liver, allowing for lower drug doses and improved tolerability.

Differentiator

Problem solved

Functional benefit

Products and services

• VR101

Quantifiable outcome

• VR101 shows superior contraceptive efficacy compared to oral progestin-only products (POPs) by avoiding peak-trough plasma variations
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Contract Manufacturing Organizations (CMOs)coreOthersVaRi Bioscience collaborates with specialized CMOs for clinical and commercial supply of vaginal ring products. The company is collaborating with specialized CMOs for manufacturing while focusing on product development and regulatory activities.

Recent moves6 records

Expansion highlights5 records

Direct peers

• HRA Pharma: European women's health specialty pharma (acquired by Perrigo) focused on reproductive health and emergency contraception. Mid-size comparable to VaRi's likely commercial ambition and target specialty prescribing audience.
• Mithra Pharmaceuticals: Belgian specialty pharma developing women's health products including vaginal ring contraceptives (Estelle) and vaginal hormone therapy (Donesta). Most direct competitor to VaRi's vaginal ring platform approach, with overlapping indication set and similar combination drug-device regulatory pathway.
• Daré Bioscience: Clinical-stage women's health biotech developing novel therapies in contraception, vaginal health, and reproductive medicine. Closely comparable business stage and indication set to VaRi, with similar capital-intensive biotech economics and platform-extension strategy.
• TherapeuticsMD (now Mayne Pharma): US women's health specialty pharma (acquired by Mayne Pharma) focused on hormone therapies including vulvovaginal atrophy treatments. Direct overlap with VaRi's VR102 indication and similar prescription-driven commercial model targeting OB/GYNs.

Broad incumbents

• AbbVie: Major women's health franchise post-Allergan acquisition including Lo Loestrin and Oriahnn for endometriosis. Competes head-to-head with VaRi's VR103 in endometriosis and has substantially greater commercial reach.
• Bayer AG: Global pharma major with one of the largest women's health franchises (oral contraceptives, IUDs, endometriosis therapies). Several VaRi founders worked at Bayer/Schering, and Bayer's portfolio overlaps VaRi's endometriosis and contraception indications directly.
• Pfizer: Global pharma with broad women's health portfolio across contraception, menopause, and endometriosis (via legacy Pharmacia Upjohn assets). Potential acquirer given overlap with VaRi's indication set.
• Organon & Co. Global women's health spinoff from Merck that markets NuvaRing, the leading commercialized contraceptive vaginal ring. Head of Product Development Herman Vromans spent 20+ years at Organon/Schering Plough/Merck. Sets the commercial benchmark VaRi's VR101 must beat.

Emerging players

• Evofem Biosciences: Women's health specialty company commercializing Phexxi, a non-hormonal contraceptive vaginal gel. Overlapping commercial call point (OB/GYNs and women's health providers) and reproductive health focus, though different mechanism.
• Agile Therapeutics: Women's health company with Twirla, a combination hormonal contraceptive patch, demonstrating late-stage regulatory pathway in women's health drug delivery. Comparable regulatory and commercial-readiness profile to VaRi's intended path.

Market position

Strengths1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vari-bioscience-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VaRi bioscience